External radiotherapy and extrahepatic bile duct cancer. 1991

R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
Department of Surgery, University Hospital Leiden, The Netherlands.

The hospital records of patients with extrahepatic bile duct cancer who where treated surgically between 1968 and 1983 were reviewed. Of 55 patients, 16 (29%) received radiotherapy after surgery. The total dose given ranged from 40 to 60 Gy. Median follow-up time for analysis was 4.0 months and lasted until January 1988. The overall median survival was 4 months (range 0-36), that of the irradiated patients was 16 months (range 2-36), and that of the 39 patients who were not irradiated was 3 months (range 0-32). When the 13 post operative deaths were excluded the median survival was 4 months. Radiotherapy did not cause any severe complications. No firm conclusion about the role of radiotherapy can be drawn from these data because the patients were not randomly chosen to receive radiotherapy and selection was therefore biased. We conclude that most patients with extrahepatic bile duct cancer still die of locoregional disease. Effective adjuvant treatments are needed and should be evaluated in prospective randomized trials.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011182 Postoperative Care The period of care beginning when the patient is removed from surgery and aimed at meeting the patient's psychological and physical needs directly after surgery. (From Dictionary of Health Services Management, 2d ed) Care, Postoperative,Postoperative Procedures,Procedures, Postoperative,Postoperative Procedure,Procedure, Postoperative
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006500 Hepatic Duct, Common Predominantly extrahepatic bile duct which is formed by the junction of the right and left hepatic ducts, which are predominantly intrahepatic, and, in turn, joins the cystic duct to form the common bile duct. Common Hepatic Duct,Hepatic Duct,Common Hepatic Ducts,Duct, Common Hepatic,Duct, Hepatic,Ducts, Common Hepatic,Ducts, Hepatic,Hepatic Ducts,Hepatic Ducts, Common
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
January 1987, Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica,
R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
October 1999, International journal of radiation oncology, biology, physics,
R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
April 1998, American journal of clinical oncology,
R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
March 1981, New York state journal of medicine,
R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
March 2017, The British journal of radiology,
R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
February 1981, Zhonghua zhong liu za zhi [Chinese journal of oncology],
R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
January 1996, Ryoikibetsu shokogun shirizu,
R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
September 1990, Zhonghua zhong liu za zhi [Chinese journal of oncology],
R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
April 1984, The Journal of the Oklahoma State Medical Association,
R A Tollenaar, and C J van de Velde, and C W Taat, and D Gonzalez Gonzalez, and J W Leer, and J Hermans
December 2017, The British journal of radiology,
Copied contents to your clipboard!